METHOD FOR CHOOSING PSYCHOPHARMACOLOGICAL THERAPY OF PANIC DISORDER Russian patent published in 2013 - IPC A61K31/197 A61K31/5513 A61P25/24 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely psychiatry, and may be used for treating the patients suffering panic disorders. If the patient is diagnosed with panic disorder, clonazepam 2 mg and pregabalin 150 mg a day are prescribed. The biochemical blood serotonin examination is performed as early as possible. An antidepressant is prescribed if observing the serotonin metabolism values. The values appearing to be consistent with the norm require no antidepressant therapy. In both cases, a length of the clonazepam therapy makes 2 weeks. Then, the dose is reduced by 25% a week. The dose of pregabalin is not changed. The onset of aggravations requires the previous dose of clonazepam before the reduction caused aggravation and the increasing dose of pregabalin by 75 mg a day. Then, 2 weeks after the state is stabilised, another attempt to withdraw clonazepam is made. After the withdrawal of clonazepam, the pregabalin therapy is continued. The preparations are gradually withdrawn 3 months after the last episode of panic attack.

EFFECT: invention enables reducing a risk of developing addiction to benzodiazepine tranquilisers and enhancing the therapeutic safety in panic disorders.

2 ex